Evaluating Tislelizumab, Lenvatinib, and FOLFOX4-HAIC as a Conversion Therapy for Unresectable Hepatocellular Carcinoma  

作　　者：Kai Tan Xiaojun He Haoran Yuan Shoujie Zhao Chenyu Gong Yaoyao Zhao Haiyan Nan Li Zang Zhonghua Luo Xilin Du 

机构地区：[1]Department of General Surgery,Tangdu Hospital,Air Force Medical University(Fourth Military Medical University),Xi'an 710038,Shanxi Province,China [2]Department of Infectious Disease,The 964th Hospital of the People's Liberation Army of China,Changchun 130062,Jilin Province,China [3]Graduate School of Xi'an Medical University,Xi'an 710021,Shanxi Province,China [4]Department of Radiology,Tangdu Hospital,Air Force Medical University(Fourth Military Medical University),Xi'an 710038,Shanxi Province,China [5]Department of Intervention Center,Tangdu Hospital,Air Force Medical University(Fourth Military Medical University),Xi'an 710038,Shanxi Province,China

出　　处：《iLIVER》2023年第3期163-169,共7页国际肝胆健康（英文）

摘　　要：Background and aims:Conversion therapy downstages tumors and renders patients with unresectable hepatocel-lular carcinoma(HCC)eligible for radical resection.This study aimed to evaluate the efficacy and safety of tislelizumab plus lenvatinib and hepatic artery infusion chemotherapy with oxaliplatin,fluorouracil,and leuco-vorin(FOLFOX4-HAIC)as a first-line conversion therapy.Methods:Clinical data from HCC patients who were treated with the triple therapy between April 2021 and April 2022 were retrospectively analyzed.The primary outcome included objective response rate(ORR),disease control rate(DCR),conversion resection rate(CRR),and treatment-related adverse events(TRAEs).Results:A total of 18 patients completed conversion therapy assessment,which ended on March 27,2023.The patients had a median age of 55.5(37–72)years,and 94.4%were male.According to mRECIST,tumor shrinkage was observed in all patients,with an ORR of 94.4%(17/18),a DCR of 94.4%(17/18),and a median time to response of 1.4(0.7–3.0)months.Successful conversion was observed in 61.1%(11/18)of patients(mRECIST).The CRR and pathological complete response were 38.9%(7/18)and 57.1%(4/7),respectively.The median progression-free survival(PFS)was 17.8 months,while median overall survival was not reached.The 6-and 9-month PFS rates were 83.3%and 66.7%,respectively.The most common TRAE(16/18 patients,88.9%)was an increase in aspartate aminotransferase levels.Conclusion:Tislelizumab combined with lenvatinib and FOLFOX4-HAIC achieved a high conversion rate and acceptable toxicity in patients with unresectable HCC,suggesting that this combination may represent a new conversion strategy for this population.

关 键 词：FOLFOX Hepatocellular carcinoma Hepatic artery infusion chemotherapy Lenvatinib Tislelizumab 

分 类 号：R735.7[医药卫生—肿瘤]